Peptide Half-Life and Stability: What DAC, PEG, Acetylation and Aib Actually Do

The phrase "peptide stability" covers two quite separate issues: how long material survives chemically in a vial, counted in months at a given temperature, and how long a peptide persists in a living system, counted in minutes to days. DAC, PEGylation, acetylation, amidation and D-amino-acid substitution all address the second problem, and knowing which enzyme each modification defeats is the quickest route to predicting how an analogue will behave in an experiment. Below we separate the two kinds of stability, work through the four clearance routes a peptide must survive, tabulate reported half-lives across our range and run the decay arithmetic. All figures come from published pharmacokinetic studies of the reference molecules, not from our own material.

Circulating half-life and shelf life are separate clocks

Mixing them up leads to errors in both directions: a peptide with a plasma half-life of one minute may sit unchanged in a freezer for three years, while a molecule engineered to circulate for a week is no better protected against a freeze–thaw event than its unmodified parent.

Four routes by which peptides are cleared

1. Exopeptidases. Enzymes nibble inward from the ends — aminopeptidases from the N-terminus, carboxypeptidases from the C-terminus — and capping the relevant end stops both.
2. Endopeptidases, DPP-4 in particular. Dipeptidyl peptidase-4 strips the first two residues from any peptide carrying alanine or proline at position 2, a description that fits native GLP-1, GIP, GHRH and many more. That one enzyme accounts for most of the design space occupied by incretin and GHRH analogues.
3. Filtration at the kidney. The glomerulus passes molecules freely below roughly 30–50 kDa, and virtually every research peptide is far smaller, so unbound peptide disappears on its first pass through the kidney. The only remedies are pushing apparent size above the cutoff or binding to a large plasma protein.
4. Receptor internalisation and hepatic uptake. Agonists are removed along with the receptors they occupy, establishing a floor that no modification can eliminate.

What each modification achieves

Substituting position 2 to block DPP-4

Native GLP-1 lasts about 1.5–2 minutes in plasma because DPP-4 cuts it at position 2. Swapping that alanine for a non-standard residue — Aib (α-aminoisobutyric acid) in semaglutide and tirzepatide, or D-Ala in a number of GHRH analogues — destroys the enzyme's recognition of the substrate. The same approach shows up in CJC-1295 without DAC, where four substitutions on the GHRH(1-29) backbone provide DPP-4 resistance and lift the reported half-life from GHRH's few minutes to around 30 minutes.

Binding albumin: DAC and fatty-acid acylation

Half an hour is still brief. The next move is to attach the peptide to serum albumin — a 66.5 kDa protein too large to filter, with a half-life of roughly 19 days. Two chemistries predominate:

• DAC (drug affinity complex) — a maleimidoproprionyl group that bonds covalently to albumin's free cysteine-34 thiol. This is precisely why CJC-1295 with DAC reports a half-life in days rather than minutes, at the cost of a continuous instead of pulsatile exposure profile — a distinction of real consequence in growth-hormone research.
• Fatty-acid acylation — a C16 or C18 diacid chain, typically attached through a linker, that binds albumin reversibly and non-covalently. It is how semaglutide reaches a reported terminal half-life around 165 hours (roughly a week) and liraglutide about 13 hours, the gap between them owing mainly to linker and chain chemistry.

PEGylation: purchasing bulk

Adding a polyethylene glycol chain does not render a peptide protease-proof; it makes it large and slippery. A PEG of 5–40 kDa lifts the hydrodynamic radius past the glomerular cutoff and sterically masks cleavage sites. PEG-MGF exists for exactly that purpose: unmodified MGF is reported to clear within minutes, whereas the PEG chain pushes that into hours. The costs are reduced receptor affinity per molecule, a heterogeneous product where the PEG is polydisperse, and a labelled molecular weight consisting largely of polymer.

Capping the ends and using non-natural residues

• Acetylating the N-terminus shields the free amine from aminopeptidases and adds 42.04 Da, which is why TB-500 comes as Ac-LKKTETQ.
• Amidating the C-terminus stops carboxypeptidases, removes a negative charge and, for many native signalling peptides, is necessary for receptor activity at all.
• Doing both, as in N-Acetyl Semax Amidate, seals off a short peptide that would otherwise be attacked from either direction.
• D-amino acids and cyclisation give the backbone a geometry that proteases evolved on L-peptides cannot recognise. The notation for all of these appears in how to read a peptide sequence.

Working through the decay arithmetic

Because elimination follows first-order kinetics, the fraction left after time t equals 0.5 raised to (t ÷ half-life). Two consequences repay explicit calculation:

1. Clearance. Given a 30-minute half-life, two hours represents four half-lives: 0.5⁴ leaves 6.25%. At three hours, six half-lives leave 1.6%. A molecule at this end of the range is essentially gone within one working day.
2. Given a 7-day half-life, two hours is 0.0119 half-lives and 99.2% remains. Sampling schedules suited to one molecule are meaningless for the other.
3. Steady state. With repeated administration, a plateau is approached after roughly five half-lives — about 2.5 hours for the 30-minute molecule and about 35 days for the 7-day one. Study duration follows from that figure, not from convenience.

What none of these modifications alters

Shelf life obeys a different chemistry. As a rule of thumb taken from Arrhenius behaviour, the rates of the degradation pathways that matter roughly double for every 10 °C increase, which is why a lyophilized vial stable for years at −20 °C may be specified in weeks at 25 °C. A PEGylated or albumin-binding analogue gains nothing here, because the modification defends against enzymes, not against hydrolysis, oxidation or moisture ingress.

• Exclude water. Residual moisture drives most solid-state degradation, and opening a vial while it is still cold draws condensation onto the powder.
• Exclude oxygen and light. Methionine, cysteine and tryptophan residues are the usual victims.
• Minimise freeze–thaw cycles. Solutes concentrate at the advancing ice front and promote aggregation, so aliquot instead, as described in aliquoting peptide solutions.

Put briefly: change the molecule to alter what happens inside an organism, and change the storage conditions to control what happens inside a vial. Neither substitutes for the other.